EXEL vs LMAT
Exelixis vs LeMaitre Vascular, Inc. — AI-powered side-by-side comparison
VS
LMAT
LeMaitre Vascular, Inc.
57
Watch
| Metric | EXEL | LMAT |
|---|
| AI Score |
67
|
57
|
| Price |
$51.30
|
$82.83
|
| P/E Ratio |
15.60×
|
28.57×
|
| ROE |
36.2%
|
14.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
72.9%
|
| Debt / Equity |
0.09×
|
0.45×
|
| Dividend Yield |
0.0%
|
1.1%
|
| RSI (14) |
41.0
|
31.2
|
| Beta |
0.422
|
0.524
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus LMAT.
EXEL leads by 10 points.
EXEL scores 67/100 (Buy) versus LMAT at 57/100 (Watch).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
LMAT Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 38.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 34.4% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 28.6 is moderate-to-rich — Value
- Price-to-book of 4.7x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical